IBIO on Nasdaq

iBio, Inc.

American pharmaceutical preparations company based in San Diego.

Price unavailable

Last updated Oct 18, 2026.

Overview

$100.0KRevenue, fiscal 2026²

-$33.0MNet income, fiscal 2026²

Compare with GRI Bio, Inc., Actinium Pharmaceuticals, Inc. or Citius Pharmaceuticals, Inc., or pick any stock.

TickerIBIO on Nasdaq
IndustryPharmaceutical Preparations
HeadquartersDover, United States
Incorporated inDE³
Business address600 Madison Avenue, Suite 1601, New York, Ny 10022-1737³
Filer categoryNon-accelerated filer, Smaller reporting company³

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

-35141.0%Operating margin²

-33044.0%Net margin²

-75.0%Revenue growth, 2026²

-38.6%Return on equity²

-$23.8MFree cash flow²

Where the money goes

Where each dollar of revenue went, fiscal 2026

Research and development

Research and development100¢$19.6M

Out of $100.0K in revenue.² The company lost money this year.

Financial statements

Revenue⁴⁵⁶⁷⁸⁹²$100.0K in 2026−95% since 2019

Gross profit⁵⁶$2.2M in 2022+132% since 2020

Operating income⁴⁵⁶⁷⁸⁹²-$35.1M in 2026+123% since 2019

Net income⁴⁵⁶⁸⁹²-$33.0M in 2026+88% since 2019

Every line of the income statement as filed: the last 2 fiscal years, latest first.²

Period ending	2026-06-30	2025-06-30
Revenue	$100.0K	$400.0K
Research and development	$19.6M	$8.3M
General and administrative	$10.6M	$10.7M
Impairment of indefinite-lived intangible asset	$5.0M	$0
Total operating expenses	$35.2M	$19.0M
Operating loss	-$35.1M	-$18.6M
Interest income	$2.1M	$437.0K
Interest expense	-$53.0K	-$212.0K
Total other income	$2.1M	$225.0K
Net loss before income taxes	-$33.0M	-$18.4M
Income tax expense	$0	$0
Net loss	-$33.0M	-$18.4M
Other comprehensive loss - unrealized loss on on debt securities	-$45.0K
Comprehensive loss	-$33.1M	-$18.4M
Loss per common share - basic	-$0.32	-$1.75
Loss per common share - diluted	-$0.32	-$1.75
Weighted-average common shares outstanding - basic	104.1M shares	10.5M shares
Weighted-average common shares outstanding - diluted	104.1M shares	10.5M shares

Total assets⁴⁵⁶⁷⁸⁹²$99.1M in 2026+224% since 2019

Total liabilities⁴⁵⁶⁷⁸⁹²$13.4M in 2026−52% since 2019

Shareholders’ equity⁴⁵⁶⁷⁸⁹²$85.7M in 2026+3380% since 2019

Cash⁵⁶⁷⁸⁹²$56.4M in 2026+1176% since 2019

Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.²

Period ending	2026-06-30	2025-06-30	2024-06-30
Cash and cash equivalents	$56.4M	$8.6M
Accounts receivable - trade, net of allowance for credit losses of $65 and $0 as of June 30, 2026 and June 30, 2025, respectively			$0
Investments in debt securities (adjusted cost $31,689 and $0 as of June 30, 2026 and June 30, 2025, respectively - see Note 6)	$31.6M
Subscription receivable		$105.0K
Promissory note receivable and accrued interest	$1.1M
Prepaid expenses and other current assets	$3.1M	$1.0M
Total Current Assets	$92.2M	$9.7M
Restricted cash	$228.0K	$210.0K
Promissory note receivable and accrued interest		$1.1M
Finance lease right-of-use assets, net of accumulated amortization		$68.0K
Operating lease right-of-use asset, net of accumulated amortization	$1.7M	$2.1M
Fixed assets, net of accumulated depreciation	$3.1M	$3.2M
Intangible assets, net of accumulated amortization	$1.8M	$6.8M
Prepaid expenses - noncurrent	$73.0K
Security deposits	$10.0K	$26.0K
Total Assets	$99.1M	$23.2M
Accounts payable	$4.4M	$2.2M
Accrued expenses	$5.6M	$1.3M
Finance lease obligations		$53.0K
Operating lease obligation - current portion	$546.0K	$490.0K
Equipment financing payable - current portion		$64.0K
Term promissory note		$766.0K
Contract liabilities	$1.1M	$1.2M	$200.0K
Total Current Liabilities	$11.7M	$6.1M
Operating lease obligation - net of current portion	$1.7M	$2.2M
Total Liabilities	$13.4M	$8.3M
Common Stock - $0.001 par value; 275,000,000 shares authorized; 55,698,561 and 19,349,201 shares issued and outstanding as of June 30, 2026 and June 30, 2025, respectively	$56.0K	$19.0K
Additional paid-in capital	$451.0M	$347.1M
Accumulated other comprehensive loss	-$45.0K
Accumulated deficit	-$365.3M	-$332.2M
Total Stockholders' Equity	$85.7M	$14.9M
Total Liabilities and Stockholders' Equity	$99.1M	$23.2M
Allowance for credit losses	$65.0K	$0
Investments in debt securities, adjusted cost	$31.7M	$0
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	1.0M shares	1.0M shares
Preferred stock, shares issued	0 shares	0 shares
Preferred stock, shares outstanding	0 shares	0 shares
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	275.0M shares	275.0M shares
Common stock, shares issued	55.7M shares	19.3M shares
Common stock, shares outstanding	55.7M shares	19.3M shares

Period ending	2026-06-30	2025-06-30	2024-06-30
Cash and cash equivalents	$56.4M	$8.6M
Accounts receivable - trade, net of allowance for credit losses of $65 and $0 as of June 30, 2026 and June 30, 2025, respectively			$0
Investments in debt securities (adjusted cost $31,689 and $0 as of June 30, 2026 and June 30, 2025, respectively - see Note 6)	$31.6M
Subscription receivable		$105.0K
Promissory note receivable and accrued interest	$1.1M
Prepaid expenses and other current assets	$3.1M	$1.0M
Total Current Assets	$92.2M	$9.7M
Restricted cash	$228.0K	$210.0K
Promissory note receivable and accrued interest		$1.1M
Finance lease right-of-use assets, net of accumulated amortization		$68.0K
Operating lease right-of-use asset, net of accumulated amortization	$1.7M	$2.1M
Fixed assets, net of accumulated depreciation	$3.1M	$3.2M
Intangible assets, net of accumulated amortization	$1.8M	$6.8M
Prepaid expenses - noncurrent	$73.0K
Security deposits	$10.0K	$26.0K
Total Assets	$99.1M	$23.2M
Accounts payable	$4.4M	$2.2M
Accrued expenses	$5.6M	$1.3M
Finance lease obligations		$53.0K
Operating lease obligation - current portion	$546.0K	$490.0K
Equipment financing payable - current portion		$64.0K
Term promissory note		$766.0K
Contract liabilities	$1.1M	$1.2M	$200.0K
Total Current Liabilities	$11.7M	$6.1M
Operating lease obligation - net of current portion	$1.7M	$2.2M
Total Liabilities	$13.4M	$8.3M
Common Stock - $0.001 par value; 275,000,000 shares authorized; 55,698,561 and 19,349,201 shares issued and outstanding as of June 30, 2026 and June 30, 2025, respectively	$56.0K	$19.0K
Additional paid-in capital	$451.0M	$347.1M
Accumulated other comprehensive loss	-$45.0K
Accumulated deficit	-$365.3M	-$332.2M
Total Stockholders' Equity	$85.7M	$14.9M
Total Liabilities and Stockholders' Equity	$99.1M	$23.2M
Allowance for credit losses	$65.0K	$0
Investments in debt securities, adjusted cost	$31.7M	$0
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	1.0M shares	1.0M shares
Preferred stock, shares issued	0 shares	0 shares
Preferred stock, shares outstanding	0 shares	0 shares
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	275.0M shares	275.0M shares
Common stock, shares issued	55.7M shares	19.3M shares
Common stock, shares outstanding	55.7M shares	19.3M shares

Cash from operations⁴⁵⁶⁷⁸⁹²-$23.2M in 2026+66% since 2019

Capital spending⁴⁵⁶⁷⁸⁹²$578.0K in 2026−37% since 2019

Free cash flow⁴⁵⁶⁷⁸⁹²-$23.8M in 2026+60% since 2019

Every line of the cash flow as filed: the last 2 fiscal years, latest first.²

Period ending	2026-06-30	2025-06-30
Net loss	-$33.0M	-$18.4M
Share-based compensation	$1.4M	$1.5M
Amortization of intangible assets	$20.0K	$20.0K
Amortization of finance lease right-of-use assets	$68.0K	$271.0K
Amortization of operating lease right-of-use assets	$384.0K	$351.0K
Depreciation of fixed assets	$558.0K	$484.0K
Accrued interest receivable on promissory note receivable	-$80.0K	-$62.0K
Amortization of premiums/(accretion of discounts) on debt securities, net	-$194.0K	$0
Provision for credit losses	$65.0K
Impairment of fixed assets	$107.0K
Impairment of intangible assets	$5.0M
Accounts receivable - trade	-$65.0K
Prepaid expenses and other current assets	-$2.2M	-$408.0K
Prepaid expenses - noncurrent	-$73.0K
Security deposit	$16.0K
Accounts payable	$2.2M	$1.8M
Accrued expenses	$3.1M	-$758.0K
Operating lease obligations	-$490.0K	-$436.0K
Contract liabilities	-$50.0K	$250.0K
Net cash used in operating activities	-$23.2M	-$15.3M
Purchases of debt securities	-$42.3M
Redemption of debt securities	$10.8M
Payment received for interest and principal on promissory note receivable	$75.0K	$758.0K
Purchases of fixed assets	-$578.0K	-$16.0K
Net cash (used in) provided by investing activities	-$32.0M	$742.0K
Proceeds from sales of common stock	$3.5M	$3.5M
Proceeds from sales of pre-funded warrants	$72.7M
Proceeds from the exercise of warrants for pre-funded warrants	$18.1M
Proceeds from the exercise of warrants for common stock	$15.3M
Payments made for costs to acquire capital	-$5.9M	-$294.0K
Proceeds from Warrant Inducement Transaction		$6.2M
Proceeds from the exercise of stock options		$130.6K
Subscription receivable	$105.0K
Payment of equipment financing loan	-$64.0K	-$178.0K
Payment of term promissory note	-$657.0K	-$218.0K
Payment of finance lease obligation	-$53.0K	-$299.0K
Net cash provided by financing activities	$103.0M	$8.9M
Net increase (decrease) in cash, cash equivalents and restricted cash	$47.8M	-$5.6M
Costs to raise capital included in accrued expenses	$1.2M	$50.0K
Reserves related to term promissory note included in prepaid expenses	-$109.0K
Unrealized loss on available-for-sale debt securities	$45.0K
Unpaid fixed assets in accounts payable	$11.0K
Indefinite-lived intangible asset addition		$1.5M
Shares issued to AstralBio for license fee		-$750.0K
Credit provided by AstralBio		-$750.0K
Subscription receivable		$105.0K
Costs to raise capital paid directly from gross proceeds		$81.0K
Cash paid during the year for interest	$72.0K	$212.0K

Compare iBio, Inc. with another company

Leadership

Who has led iBio, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

Chair

President

Robert L. Erwin2008–2020

Chief financial officer

Chief operating officer

Randy Joe Maddux2020–2022

2010201520202025

Chief executive officerMartin Brenner Jan 24, 2023 to Jan 24, 2023¹²
Chief executive officerThomas Francis 3rd Isett Mar 16, 2020 to Sep 12, 2022¹³
Chief executive officerRobert Kay Aug 12, 2008 to May 31, 2019¹⁴
ChairThomas Francis 3rd Isett Mar 16, 2020 to Sep 12, 2022¹³
ChairRobert Kay Aug 12, 2008 to May 31, 2019¹⁴
PresidentRobert L. Erwin Aug 12, 2008 to Jun 8, 2020¹⁵
Chief financial officerFelipe Duran Feb 14, 2023 to now¹⁶
Chief financial officerJames P. Mullaney Apr 5, 2017 to May 29, 2020¹⁷
Chief financial officerMark A. Giannone Apr 7, 2014 to Apr 5, 2017¹⁸
Chief financial officerScott Kain Mar 4, 2013 to Mar 4, 2013¹⁹
Chief financial officerDouglas Beck May 10, 2011 to May 10, 2011²⁰
Chief financial officerDina Masi Aug 12, 2008 to Aug 12, 2008²¹
Chief operating officerRandy Joe Maddux Dec 2, 2020 to Mar 14, 2022²²

Board members and other officers (28)

Chief Medical OfficerMolly Carr Aug 4, 2026 to now²³
Chief Scientific OfficerMartin Brenner Jan 19, 2021 to now²⁴
Principal Accounting OfficerJohn Delta Oct 5, 2020 to Oct 5, 2020²⁵
Chief Scientific OfficerRyan E. Terence Nov 21, 2012 to May 13, 2019²⁶
Senior VP, Finance & StrategyAndrea Corcoran Dec 11, 2012 to Dec 11, 2012²⁷
Chief Scientific OfficerVidadi Yusibov Mar 8, 2010 to Mar 8, 2010²⁸
Chief Scientific OfficerGeoffrey C. Schild Aug 12, 2008 to Aug 12, 2008²⁹
VP, Bus. Dev. and MarketingJennifer L. Kmiec Aug 12, 2008 to Aug 12, 2008³⁰
Board memberElizabeth Stoner May 15, 2026 to now³¹
Board memberMartin Brenner Jan 13, 2025 to now³²
Board memberDavid Arkowitz Nov 25, 2024 to now³³
Board memberAntonio Bernardino Guimaraes Parada Dec 9, 2024 to now³⁴
Board memberEvert B. Schimmelpennink Jun 9, 2021 to now³⁵
Board memberRobert Kay Jun 16, 2020 to Oct 28, 2020³⁶
Board memberAlexandra Kropotova Oct 16, 2020 to now³⁷
Board memberGary Sender Oct 16, 2020 to now³⁸
Board memberLinda Washington Armstrong Oct 16, 2020 to Dec 13, 2021³⁹
Board memberThomas Francis 3rd Isett Apr 10, 2019 to Nov 5, 2019⁴⁰
Board memberSeymour Flug Dec 21, 2012 to May 31, 2019⁴¹
Board memberJules A. Musing Jun 30, 2011 to Jul 26, 2012⁴²
Board memberPhilip K. Russell Mar 11, 2010 to Aug 14, 2019⁴³
Board memberPamela Bassett Apr 12, 2010 to Apr 12, 2010⁴⁴
Board memberArthur Y. Elliott Dec 3, 2010 to May 31, 2019⁴⁵
Board memberGlenn Chang Aug 12, 2008 to Dec 13, 2021⁴⁶
Board memberHill (ret) James T. General Aug 12, 2008 to Dec 13, 2021⁴⁷
Board memberJohn D. McKey Jr. Aug 12, 2008 to Dec 13, 2021⁴⁸
Board memberVidadi Yusibov Aug 12, 2008 to Aug 12, 2008⁴⁹
General counselMarc Banjak Aug 14, 2024 to now⁵⁰

Former names

iBioPharma, Inc.Jul 16, 2008 to Aug 14, 2009³
InB:Biotechnologies, Inc.Mar 7, 2008 to Jul 17, 2008³

Timeline

Jan 24, 2023New chief executive Martin Brenner becomes CEO¹²
Mar 16, 2020New chief executive Thomas Francis 3rd Isett becomes CEO¹³
Aug 12, 2008New chief executive Robert Kay becomes CEO¹⁴

Filings

349 filings to the SEC since October 2021: 6 annual reports, 17 quarterly reports, 100 major events, 81 insider forms, 46 large holders, 4 private raises, 95 other. The latest 20:

The 349 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 46 such filings since October 2021, the latest 10:

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Money raised

Private offerings the company reported to the SEC on Form D.

Jan 8, 2026Raised $26 million in a private offering of securities Form D: 7 investors so far Form D
Apr 29, 2025Raised $11.1 million in a private offering of securities Form D: 5 investors so far Form D
Mar 26, 2024Raised $15.1 million in a private offering of equity Form D: 8 investors so far Form D
Aug 4, 2023Filed a private offering of equity Form D: $10 million offered in all Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 55. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Affinity Asset Advisors, LLC	4,007,881	$7.0M	0.3%	+900,681
Cormorant Asset Management, LP	3,570,000	$6.2M	0.3%	New
Silverarc Capital Management, LLC	3,520,490	$6.2M	0.7%	+3,294,490
Vestal Point Capital, LP	2,600,000	$4.5M	0.1%	New
Vanguard Capital Management LLC	2,098,151	$3.7M	0.0%	+1,009,852
Frazier Life Sciences Management, L.P.	1,953,467	$3.4M	0.1%	No change
Ensign Peak Advisors, Inc	1,832,457	$3.2M	0.0%	New
Woodline Partners LP	1,776,547	$3.1M	0.0%	New
Millennium Management LLC	1,651,473	$2.9M	0.0%	+101,623
Citadel Advisors LLC	1,384,029	$2.4M	0.0%	+427,600
Balyasny Asset Management L.P.	1,170,893	$2.0M	0.0%	+159,938
Bank Of America Corp /de/	1,121,492	$2.0M	0.0%	+831,079
Ikarian Capital, LLC	957,062	$1.7M	0.3%	No change
Sio Capital Management, LLC	904,268	$1.6M	0.3%	No change
Marshall Wace, Llp	904,132	$1.6M	0.0%	+283,530
Geode Capital Management, LLC	500,816	$876.6K	0.0%	+113,249
Walleye Capital LLC	500,375	$875.7K	0.0%	+111,821
Squarepoint Ops LLC	498,872	$873.0K	0.0%	New
Noesis Capital Mangement Corp	405,000	$708.8K	0.1%	+93,500
Two Sigma Investments, LP	400,667	$701.2K	0.0%	−8,191
Ally Bridge Group (NY) LLC	390,147	$682.8K	0.9%	New
ADAR1 Capital Management, LLC	375,531	$657.2K	0.0%	−94,347
Verdad Advisers, LP	298,927	$523.1K	0.5%	+242,609
Vanguard Fiduciary Trust Co	286,875	$502.0K	0.0%	+81,860
Boothbay Fund Management, LLC	254,412	$445.2K	0.0%	No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARiBio, Inc. filings on SEC EDGAR
2
SEC EDGARiBio, Inc. 10-K for fiscal 2026
3
SEC EDGARiBio, Inc. filings on SEC EDGAR
4
SEC EDGARiBio, Inc. 10-K for fiscal 2019
5
SEC EDGARiBio, Inc. 10-K for fiscal 2020
6
SEC EDGARiBio, Inc. 10-K for fiscal 2021
7
SEC EDGARiBio, Inc. 10-K for fiscal 2022
8
SEC EDGARiBio, Inc. 10-K for fiscal 2023
9
SEC EDGARiBio, Inc. 10-K for fiscal 2024
10
SEC EDGARiBio, Inc. 10-Q for fiscal 2025
11
SEC EDGARiBio, Inc. 10-Q for fiscal 2026
12
SEC EDGARMartin Brenner, Chief executive officer
13
SEC EDGARThomas Francis 3rd Isett, Chief executive officer
14
SEC EDGARRobert Kay, Chief executive officer
15
SEC EDGARRobert L. Erwin, President
16
SEC EDGARFelipe Duran, Chief financial officer
17
SEC EDGARJames P. Mullaney, Chief financial officer
18
SEC EDGARMark A. Giannone, Chief financial officer
19
SEC EDGARScott Kain, Chief financial officer
20
SEC EDGARDouglas Beck, Chief financial officer
21
SEC EDGARDina Masi, Chief financial officer
22
SEC EDGARRandy Joe Maddux, Chief operating officer
23
SEC EDGARMolly Carr, Chief Medical Officer
24
SEC EDGARMartin Brenner, Chief Scientific Officer
25
SEC EDGARJohn Delta, Principal Accounting Officer
26
SEC EDGARRyan E. Terence, Chief Scientific Officer
27
SEC EDGARAndrea Corcoran, Senior VP, Finance & Strategy
28
SEC EDGARVidadi Yusibov, Chief Scientific Officer
29
SEC EDGARGeoffrey C. Schild, Chief Scientific Officer
30
SEC EDGARJennifer L. Kmiec, VP, Bus. Dev. and Marketing
31
SEC EDGARElizabeth Stoner, Board member
32
SEC EDGARMartin Brenner, Board member
33
SEC EDGARDavid Arkowitz, Board member
34
SEC EDGARAntonio Bernardino Guimaraes Parada, Board member
35
SEC EDGAREvert B. Schimmelpennink, Board member
36
SEC EDGARRobert Kay, Board member
37
SEC EDGARAlexandra Kropotova, Board member
38
SEC EDGARGary Sender, Board member
39
SEC EDGARLinda Washington Armstrong, Board member
40
SEC EDGARThomas Francis 3rd Isett, Board member
41
SEC EDGARSeymour Flug, Board member
42
SEC EDGARJules A. Musing, Board member
43
SEC EDGARPhilip K. Russell, Board member
44
SEC EDGARPamela Bassett, Board member
45
SEC EDGARArthur Y. Elliott, Board member
46
SEC EDGARGlenn Chang, Board member
47
SEC EDGARHill (ret) James T. General, Board member
48
SEC EDGARJohn D. McKey Jr., Board member
49
SEC EDGARVidadi Yusibov, Board member
50
SEC EDGARMarc Banjak, General counsel